The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence

VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast Progenitors

(2011) Xin Lu et al.   CANCER CELL

Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs

(2011) Qing Chen et al.   CANCER CELL

Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs

(2011) Thordur Oskarsson et al.   NATURE MEDICINE

Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases—elevated Bmi-1 expression in late breast cancer relapses

(2011) Kristiina Joensuu et al.   VIRCHOWS ARCHIV

Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer

(2009) James Mansell et al.   BREAST CANCER RESEARCH AND TREATMENT

Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis

(2009) J. L.F. Bosco et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? 

(2008) PAUL GOSS et al.   APMIS

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

(2008) James J. Dignam et al.   BREAST CANCER RESEARCH AND TREATMENT

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen

(2008) Hagen Kennecke et al.   CANCER

Tumor dormancy: Elevated expression of stanniocalcins in late relapsing breast cancer

(2008) Kristiina Joensuu et al.   CANCER LETTERS

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

(2008) A. M. Brewster et al.   JNCI-Journal of the National Cancer Institute

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY